Background: Aspirin exacerbated respiratory disease (AERD) consists of nasal polyposis, rhinosinusitis, asthma, and aspirin (ASA) sensitivity.
Objective: This article details how to diagnose and treat AERD and describes the procedures associated with ASA challenge and desensitization, benefits associated with ASA desensitization, and appropriate doses for treatment.
Methods: Criteria for diagnosis of AERD as well as desensitization protocols for oral ASA challenge and combined intranasal ketorolac and oral ASA challenge, are detailed in this article based on literature review.
Results: AERD requires a multidimensional approach to treat the disease given the multiple conditions. With successful ASA desensitization and maintenance of ASA administration, all patients are able to achieve ASA tolerance and select patients are able to achieve improvement in clinical markers such as global scores and reduction in use of topical and systemic corticosteroids.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906520 | PMC |
| http://dx.doi.org/10.2500/ajra.2012.26.3721 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Auditory Environment at Early Intervention Groups for Young Children With Hearing Loss: Signal to Noise Ratio, Background Noise, and Reverberation.
Ear Hear
January 2025
Dutch Foundation of the Deaf and Hard of Hearing Child (NSDSK), Amsterdam, The Netherlands.
Objectives: One important aspect in facilitating language access for children with hearing loss (HL) is the auditory environment. An optimal auditory environment is characterized by high signal to noise ratios (SNRs), low background noise levels, and low reverberation times. In this study, the authors describe the auditory environment of early intervention groups specifically equipped for young children with HL.
View Article and Find Full Text PDFNew Ionic Liquid Forms of Antituberculosis Drug Combinations for Optimized Stability and Dissolution.
AAPS PharmSciTech
January 2025
Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
Isoniazid (INH) and rifampicin (RIF) are the two main drugs used for the management of tuberculosis. They are often used as a fixed drug combination, but their delivery is challenged by suboptimal solubility and physical instability. This study explores the potential of active pharmaceutical ingredient-ionic liquids (API-ILs) to improve the physicochemical and pharmaceutical properties of INH and RIF.
View Article and Find Full Text PDFTrans-Coronary Sinus Intra-Septal Radiofrequency Ablation (TIRA) for Hypertrophic Obstructive Cardiomyopathy: First-in-Human Results.
Biomedicines
December 2024
Department of Internal Medicine, Pusan National University School of Medicine and Cardiology, Cardiovascular Center and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea.
Background: Current treatments for hypertrophic obstructive cardiomyopathy (HOCM), including medication, surgery, and alcohol septal ablation (ASA), have limitations in terms of efficacy and safety. To address these challenges, we developed the trans-coronary intra-septal radiofrequency ablation (TIRA) device.
Methods: This first-in-human trial was conducted to assess the efficacy and safety of the TIRA device.
Efficacy of Neoadjuvant Hypofractionated Chemoradiotherapy in Elderly Patients with Locally Advanced Rectal Cancer: A Single-Center Retrospective Analysis.
Cancers (Basel)
December 2024
Department of Surgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun 58128, Republic of Korea.
: The application of long-course chemoradiotherapy (LCRT) in elderly patients with locally advanced rectal cancer (LARC) can be challenging due to increased risks of complications associated with comorbidities and reduced functional status. This study aimed to assess the efficacy of neoadjuvant hypofractionated chemoradiotherapy (HCRT) in elderly patients with mid-to-low LARC. : We performed a retrospective review of patients diagnosed with LARC from January 2013 to December 2020 and included those aged 70 years or older.
View Article and Find Full Text PDFConsensus on the lung cancer management after third-generation EGFR-TKI resistance.
Lancet Reg Health West Pac
December 2024
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Article Synopsis
- Lung cancer is the most common type of cancer in the Asia-Pacific region, with non-small cell lung cancer (NSCLC) making up about 85% of cases, and a significant mutation rate of 40-60% in Asian patients with lung adenocarcinoma.
- Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved treatment for NSCLC with mutations, but managing resistance to these drugs is still a major issue with no standardized guidelines.
- A set of recommendations has been developed, integrating international guidelines and regional clinical experiences, to help healthcare providers classify resistance, conduct clinical testing, and devise treatment strategies for patients struggling with resistance to third-generation EGFR-TKIs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!